Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application

3 years ago

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a…

CinCor Pharma Appoints June Lee to Its Board of Directors

3 years ago

BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member…

BlueJay Therapeutics to Present at the 2nd Global IR@JPM Conference

3 years ago

SAN MATEO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BlueJay Therapeutics, a private biopharmaceutical company focused on cures for infectious…

Ascend Expands Testing Capacity with New Siemens Healthineers Strategic Relationship

3 years ago

The nation’s leading dialysis testing lab will become the biggest single-site user of Siemens Healthineers Atellica Solution analyzers in the…

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

3 years ago

CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically…

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

3 years ago

TransCon hGH (approved by the European Commission as Lonapegsomatropin Ascendis Pharma) is a once-weekly prodrug of somatropin for pediatric patients…

AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

3 years ago

XIAMEN, China and HONG KONG, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK)…

EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers

3 years ago

Represents first step towards a potential clinical treatment of locally advanced pancreatic cancer LYON, France, January 13, 2022 -- EDAP TMS…

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

3 years ago

- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with…

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

3 years ago

With the addition of psilocybin and MDMA to Health Canada’s Special Access Program, Mydecine looks to offer a package of…